Abstract
The purpose of this paper is to compare the relative mitigation efficiency of COVID-19 transmission among 23 selected countries, including 19 countries in the G20, two heavily infected countries (Iran and Spain), and two highly populous countries (Pakistan and Nigeria). This paper evaluated the mitigation efficiency for each country at each stage by using data envelopment analysis (DEA) tools and analyzed changes in mitigation efficiency across stages. Pearson correlation tests were conducted between each change to examine the impact of efficiency ranks in the previous stage on subsequent stages. An indicator was developed to judge epidemic stability and was applied to practical cases involving lifting travel restrictions and restarting the economy in some countries.
The results showed that Korea and Australia performed with the highest efficiency in preventing the diffusion of COVID-19 for the whole period covering 120 days since the first confirmed case, while the USA ranked at the bottom. China, Japan, Korea and Australia were judged to have recovered from the attack of COVID-19 due to higher epidemic stability.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded in part by the Ministry of Science and Technology (MOST) in Taiwan under grant numbers MOST 108-2410-H-227-008 to Yi-Tui Chen.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data for accumulated confirmed cases were extracted from the daily Coronavirus disease (COVID-2019) situation reports from the WHO, Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
